Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Trial in Japan for LP-300, Validates International Expansion Strategy.

Lantern Pharma has completed targeted enrollment for its Phase 2 Harmonic clinical trial in Japan for LP-300 in combination with carboplatin and pemetrexed in never-smoker patients with non-small cell lung cancer. The company enrolled 10 patients ahead of schedule across five clinical sites in Japan, demonstrating excellent execution of its international expansion strategy. The trial aims to enroll approximately 90 patients across multiple regions, including the United States and Taiwan.